Iqvia (IQV) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 26, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Eric Sherbet, See Remarks sold 4,446 shares at $278.83 ($1.2M).
- Trade date
- Nov 9, 2026
- Disclosed to the SEC
- Nov 12, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All IQV insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
IQV insider transactions (Form 4)
Open-market purchases and sales. 41 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 12SEC | Eric SherbetSee Remarks | Sell | 4,44624,989 held (−15%) | $278.83 | $1.2M | -9.7% | — |
| Sep 4SEC | James G. BerkshireSee Remarks | Sell | 2,66810,890 held (−20%) | $261.33 | $697K | -3.7% | — |
| Aug 4SEC | W. Richard StaubSee Remarks | Sell | 5,50013,312 held (−29%) | $232.68 | $1.3M | +8.2% | — |
| Aug 4SEC | Bhavik PatelSee Remarks | Sell | 1,8551,348 held (−58%) | $235.27 | $436K | +7.0% | — |
| Jul 31SEC | Ari BousbibSee Remarks | Sell | 53,191885,868 held (−6%) | $244.78 | $13.0M | +2.8% | — |
| Jul 31SEC | Ari BousbibSee Remarks | Sell | 44,039939,059 held (−4%) | $246.08 | $10.8M | +2.3% | — |
| Jul 31SEC | Eric SherbetSee Remarks | Sell | 5,00020,999 held (−19%) | $249.16 | $1.2M | +1.0% | — |
| Jul 31SEC | Ari BousbibSee Remarks | Sell | 4,584983,098 held (−0%) | $246.85 | $1.1M | +2.0% | — |
| Jul 31SEC | Ari BousbibSee Remarks | Sell | 4,465987,682 held (−0%) | $247.10 | $1.1M | +1.9% | — |
| Jul 31SEC | Keriann CherofskySee Remarks | Sell | 5582,989 held (−16%) | $245.21 | $137K | +2.6% | — |
| Dec 19SEC | Ari BousbibSee Remarks | Sell | 36,564820,599 held (−4%) | $222.43 | $8.1M | +13.2% | — |
| Oct 31SEC | Ari BousbibSee Remarks | Sell | 26,128832,171 held (−3%) | $221.31 | $5.8M | +13.7% | — |
| Oct 31SEC | Ari BousbibSee Remarks | Sell | 13,741862,899 held (−2%) | $219.29 | $3.0M | +14.8% | — |
| Oct 31SEC | Ari BousbibSee Remarks | Sell | 7,315876,640 held (−1%) | $218.32 | $1.6M | +15.3% | — |
| Oct 31SEC | Ari BousbibSee Remarks | Sell | 4,600858,299 held (−1%) | $220.11 | $1.0M | +14.3% | — |
| Oct 31SEC | Ari BousbibSee Remarks | Sell | 3,973828,198 held (−0%) | $221.97 | $882K | +13.4% | — |
| Oct 31SEC | Eric SherbetSee Remarks | Sell | 4,00027,108 held (−13%) | $219.70 | $879K | +14.6% | — |
| Oct 31SEC | Ari BousbibSee Remarks | Sell | 800883,955 held (−0%) | $217.58 | $174K | +15.7% | — |
Similar past setups: not applicable. IQV has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with IQV in the Research Lab
IQV has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Iqvia insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $39.3M of IQV stock on the open market; P/E 32.2 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
IQV insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $1.2M | 1 |
| Q3 2026 | — | 0 | $29.9M | 9 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | — | 0 | $21.5M | 8 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 IQVIA insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $39.3M. 0 of 18 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
IQV earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 27, 2026 | +5.3% | None | +2.0%S&P +0.9% | pending |
| Jul 28, 2026 | +2.6% | None | +16.1%S&P -1.3% | +5.7% |
| May 5, 2026 | -8.8% | None | +9.6%S&P +2.2% | +4.0% |
| Feb 5, 2026 | -13.3% | None | -7.4%S&P +0.6% | -6.9% |
| Oct 28, 2025 | +9.7% | None | +0.2%S&P +0.3% | +5.6% |
| Jul 22, 2025 | -3.2% | None | +22.2%S&P +0.9% | -1.6% |
| May 6, 2025 | +5.8% | None | +0.7%S&P -0.4% | -0.6% |
| Feb 6, 2025 | -0.1% | None | +1.3%S&P -0.6% | -7.9% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
IQV short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded IQV
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Markwayne MullinSenate | Bought $15,001 - $50,000 | Dec 29, 2025 | Jan 16, 2026 | +10.8% |
| John BoozmanSenate | Sold $1,001 - $15,000 | Oct 2, 2025 | Nov 15, 2025 | +23.2% |
Insiders at IQVIA
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Ari BousbibSee Remarks | — | $46.7M | Jul 31, 2026 | — | — |
| Eric SherbetSee Remarks | — | $3.4M | Nov 12, 2026 | — | — |
| W. Richard StaubSee Remarks | — | $1.3M | Aug 4, 2026 | — | — |
| James G. BerkshireSee Remarks | — | $697K | Sep 4, 2026 | — | — |
| Bhavik PatelSee Remarks | — | $436K | Aug 4, 2026 | — | — |
| Keriann CherofskySee Remarks | — | $137K | Jul 31, 2026 | — | — |
| Carol BurtDirector | — | — | Apr 27, 2026 | — | — |
| John G. DanhaklDirector | — | — | Apr 27, 2026 | — | — |
| Colleen A. GogginsDirector | — | — | Apr 27, 2026 | — | — |
| John M. LeonardDirector | — | — | Apr 27, 2026 | — | — |
| Michael J. FedockSee Remarks | — | — | Feb 17, 2026 | — | — |
| Bernd HaasSee Remarks | — | — | Feb 17, 2026 | — | — |
| Ronald E. BruehlmanSee Remarks | — | — | Feb 10, 2026 | — | — |
| Alistair GrenfellSee Remarks | — | — | Feb 10, 2026 | — | — |
Board links: companies that share insiders with IQV
Directors and executives who filed Form 4s for IQV and another company in the last 12 months.
- LTHLife Time Group Holdings John G. Danhakl Director here · Director at LTH · latest filing Nov 13, 2026
- NTLAIntellia Therapeutics John M. Leonard Director here · CEO, President at NTLA · latest filing Nov 3, 2026
- RMDResMed Carol Burt Director here · Director at RMD · latest filing Nov 20, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
IQV stock: common questions
Are IQVIA insiders buying IQV stock?
No. No IQVIA insider reported an open-market purchase of IQV in the past 12 months.
Are IQVIA insiders selling IQV stock?
6 insiders reported sales worth $39.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is IQV's P/E ratio?
IQV trades at about 32.2 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is IQV's 52-week range?
Over the past year IQV has traded between $156.66 and $279.36. It last closed at $251.69 on Nov 19, 2026.